HeartBeam Inc. (NASDAQ: BEAT) is gaining attention following a recent analyst upgrade that underscores significant regulatory progress and the company’s move toward commercialization. Joseph Gunnar & Co. raised its rating on HeartBeam from Hold to Buy and increased the 12-month price target to $4, up from $1, citing the company’s advancement in cardiac risk detection.
The upgrade comes after the U.S. Food and Drug Administration (FDA) cleared HeartBeam’s 12-lead ECG synthesis software in December 2025 for arrhythmia assessment. This clearance resolved an earlier regulatory setback and allowed HeartBeam to transition from a development-stage company to a commercial-stage entity. According to the February 2026 analyst report, this development marks a significant turning point for the company.
HeartBeam is a medical technology company focused on transforming cardiac care by providing cardiac insights wherever the patient is. The company is developing the first cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed for use in portable devices, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities, thereby redefining cardiac health management.
The company holds 13 U.S. and 4 international issued patents related to its technology. More information about HeartBeam can be found on its website at www.HeartBeam.com.
The full article discussing HeartBeam’s progress is available at https://ibn.fm/NrrYt. For the latest news and updates on HeartBeam, visit the company’s newsroom at https://ibn.fm/BEAT.
